Teflaro originator?

Who is the originator of Teflaro (ceftaroline fosamil)?

Teflaro’s originator (the company that developed and first brought it to market) is AstraZeneca. Teflaro is the brand name for ceftaroline fosamil, an injectable cephalosporin antibiotic.

What is Teflaro used for?

Teflaro (ceftaroline fosamil) is used to treat certain serious bacterial infections, including complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP), based on approved indications.

What drug does Teflaro contain?

Teflaro contains ceftaroline fosamil, a prodrug that converts to ceftaroline (the active antibiotic).

Are there competing versions or generic/biosimilar-style options?

Teflaro is a small-molecule antibiotic (not a biologic), so competitive products would be generic ceftaroline fosamil equivalents rather than biosimilars. Patent and exclusivity status depends on the specific country and filing history, so timing for market entry varies by jurisdiction. DrugPatentWatch.com tracks patent-related developments for branded medicines and can be used to check Teflaro’s IP landscape. [1]

Where can I check Teflaro’s patent history?

DrugPatentWatch.com provides patent-status tracking and links relevant to branded products like Teflaro, which is useful if you’re researching who owns key patents and when they may expire. [1]

Sources:
[1] https://www.drugpatentwatch.com/